A Randomised Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

To evaluate the efficacy as measured by I-PSS of lonidamine (50 mg, 150 mg) compared to placebo in subjects with symptomatic BPH.